Ascend Capital’s Immunomedics Inc IMMU Stock Holding History

Ascend Capital’s Portfolio IMMU Stock Details IMMU Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-579,943	Closed	-$5.12M	–	211
2017 Q2	$5.12M	Buy	+579,943	New	+$4.07M	0.24%	106

Other funds holding IMMU

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACP

Acuta Capital Partners Redwood City, California $142M AUM 783.79% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

PAI

Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

Ascend Capital's IMMU Position: Q3 2017 in Review

Ascend Capital sold out of Immunomedics Inc (IMMU) in Q3 2017, closing a stake of 579,943 shares — an estimated $5.12M sold.

Ascend Capital first reported a position in IMMU in Q2 2017 and held it in 1 quarter. The position peaked at $5.12M in Q2 2017. 150 funds tracked by Wall St. Rank hold IMMU as of Q3 2017.

Ascend Capital reported no remaining Immunomedics Inc position as of Q3 2017 after selling out during the quarter.
Ascend Capital sold 579,943 Immunomedics Inc shares in Q3 2017, an estimated $5.12M.
Ascend Capital first reported a position in Immunomedics Inc in Q2 2017 and held it in 1 quarter.
Ascend Capital's Immunomedics Inc position peaked at $5.12M in Q2 2017.
150 funds tracked by Wall St. Rank held Immunomedics Inc as of Q3 2017.

Based on Ascend Capital's 13F filing for Q3 2017, filed 13 Nov 2017.